Oct 26, 2022 / 10:00PM GMT
Unidentified Participant
Good afternoon and welcome to Genprex. I'd like to introduce the CFO, Ryan Confer.
Ryan Confer - Genprex, Inc. - CFO
All right. Thank you all for being here. Again, my name is Ryan Confer. I'm the Chief Financial Officer of Genprex. We are pioneering gene therapies for extremely large patient populations.
So just a quick note on our forward-looking statements. Anybody interested in investing in Genprex, highly encourage you to check out our website, particular our IR website, where you can read any of our SEC filings including all of our risk factors and our most recent 10-K.
So here at Genprex, we believe we have several key competitive advantages. First, we are targeting extremely large markets where patient populations have critical unmet needs with their current therapies. With cancer, and our oncology program in particular, we have a really unique non-viral gene therapy platform, which makes it very unlike every other treatment option out there. It is the first systemic gene therapy used for cancer in humans.
Genprex Inc at LD Micro Main Event Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers